Biotech startup aims to make use of humanity’s genetic outliers

Variant Bio is hunting for rare DNA that its researchers hope to turn into drugs and therapies. "Castel is the co-founder of Variant Bio, a startup that’s spent the past couple years scouring the planet for genetic outliers. His team is betting that by sequencing such people’s DNA, Variant will be able to untangle the root causes of desirable traits — superior metabolism, eyesight, immune response — and synthesize drugs and other therapies that could pass some of these benefits on to the rest of us." Ashlee Vance investigates in Bloomberg Businessweek.